[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 25 of about 25
1. Huh JW, Park YA, Lee KY, Sohn SK: Heterogeneity of adenosine triphosphate-based chemotherapy response assay in colorectal cancer--secondary publication. Yonsei Med J; 2009 Oct 31;50(5):697-703
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Heterogeneity of adenosine triphosphate-based chemotherapy response assay in colorectal cancer--secondary publication.
  • PURPOSE: Adenosine triphosphate-based chemotherapy response assay (ATP-CRA) is a well-documented and validated technology that can individualize chemotherapy for patients with lung, stomach, or breast cancer.
  • This study explored the feasibility of ATP-CRA as a chemosensitivity test in patients with colorectal cancer.
  • MATERIALS AND METHODS: A total of 118 patients who underwent surgical resection for colorectal adenocarcinoma were analyzed for chemosensitivity to 6 anticancer drugs using ATP-CRA.
  • We calculated the cell death rate (CDR) by measuring intracellular ATP levels of drug-exposed cells and untreated controls.
  • Irinotecan had the greatest responsiveness in patients with well differentiated and moderately differentiated carcinoma.
  • CONCLUSION: Our study suggests that ATP-CRA could be used to identify patients with colorectal cancer who might benefit from treatment with a specific chemotherapeutic agent.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenosine Triphosphate / metabolism. Antineoplastic Agents / pharmacology. Colorectal Neoplasms / drug therapy. Drug Screening Assays, Antitumor / methods

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gynecol Oncol. 2000 Mar;76(3):405-8 [10684718.001]
  • [Cites] J Korean Med Sci. 2008 Oct;23(5):916-9 [18955806.001]
  • [Cites] Eur J Cancer. 2002 May;38(7):872-9 [11978511.001]
  • [Cites] Anticancer Drugs. 2003 Jun;14(5):369-75 [12782944.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):23-30 [14665611.001]
  • [Cites] J Clin Oncol. 2004 Jan 15;22(2):229-37 [14657227.001]
  • [Cites] Pharm Res. 2004 Mar;21(3):406-12 [15070089.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3618-30 [15289487.001]
  • [Cites] J Clin Oncol. 2004 Sep 1;22(17):3631-8 [15289488.001]
  • [Cites] Cancer Res. 1982 Jun;42(6):2159-64 [7074595.001]
  • [Cites] Cancer Treat Rev. 1984 Mar;11 Suppl A:113-24 [6428738.001]
  • [Cites] Recent Results Cancer Res. 1984;94:1-7 [6494573.001]
  • [Cites] Hematol Oncol. 1985 Jan-Mar;3(1):1-10 [2580768.001]
  • [Cites] Cancer Treat Rep. 1986 Nov;70(11):1283-95 [2429763.001]
  • [Cites] Proc Natl Acad Sci U S A. 1987 Jul;84(14):5029-33 [3474637.001]
  • [Cites] Gynecol Oncol. 1988 Sep;31(1):191-204 [3410347.001]
  • [Cites] J Surg Oncol. 1989 Jan;40(1):4-7 [2909804.001]
  • [Cites] Eur J Cancer. 1991;27(10):1258-63 [1835595.001]
  • [Cites] J Biolumin Chemilumin. 1995 Jan-Feb;10(1):29-34 [7762413.001]
  • [Cites] Anticancer Drugs. 1996 Aug;7(6):630-5 [8913430.001]
  • [Cites] Eur J Cancer. 1997 May;33(6):960-6 [9291821.001]
  • [Cites] Ann Intern Med. 1998 Jul 1;129(1):27-35 [9652996.001]
  • [Cites] Clin Cancer Res. 1995 Mar;1(3):305-11 [9815986.001]
  • [Cites] Br J Cancer. 1999 Mar;79(9-10):1487-93 [10188895.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1625-31 [10334552.001]
  • [Cites] Anticancer Drugs. 1999 Jun;10(5):437-44 [10477162.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Anticancer Res. 2005 Sep-Oct;25(5):3453-9 [16101163.001]
  • [Cites] Cell Cycle. 2006 Apr;5(8):818-23 [16628000.001]
  • [Cites] Int J Clin Oncol. 2006 Dec;11(6):449-53 [17180513.001]
  • [Cites] Cancer. 2007 May 1;109(9):1829-35 [17366594.001]
  • [Cites] Gynecol Oncol. 2000 May;77(2):258-63 [10785475.001]
  • (PMID = 19881975.001).
  • [ISSN] 1976-2437
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 8L70Q75FXE / Adenosine Triphosphate
  • [Other-IDs] NLM/ PMC2768246
  • [Keywords] NOTNLM ; Adenosine triphosphate / chemotherapy response assay / colorectal cancer
  •  go-up   go-down


2. Kuratate S, Inoue S, Chikakiyo M, Kaneda Y, Harino Y, Hirose T, Yagi T, Saitoh S, Sumitomo M, Fujino R, Satake N: Coexistent poorly-differentiated neuroendocrine cell carcinoma and non-invasive well-differentiated adenocarcinoma in tubulovillous adenoma of the rectum: report of a case. J Med Invest; 2010 Aug;57(3-4):338-44

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Coexistent poorly-differentiated neuroendocrine cell carcinoma and non-invasive well-differentiated adenocarcinoma in tubulovillous adenoma of the rectum: report of a case.
  • A 74-years old man was referred to our hospital for treatment of a rectal mass.
  • Histological and immuno- histochemical features showed coexistent poorly-differentiated small cell neuroendocrine cell (NEC) carcinoma and non-invasive well-differentiated adenocarcinoma in tubulovillous adenoma.
  • However the chemotherapy with FOLFOX and Bevacizumab was performed postoperatively, the patient died in cancer 3 months after surgery.
  • Rectal poorly-differentiated NEC carcinomas are thought to be a tumor with a high malignant potential.
  • Recently, the UICC TNM classifications of malignant tumors, 7th edition and the Guidelines for colorectal NEC tumors of European Neuroendocrine Tumor Society have been published.
  • They would be evaluated, and effective multimodal therapy for NEC carcinomas should be established.
  • [MeSH-major] Adenocarcinoma / pathology. Adenoma, Villous / pathology. Carcinoma, Neuroendocrine / pathology. Neoplasms, Multiple Primary / pathology. Rectal Neoplasms / pathology
  • [MeSH-minor] Aged. Humans. Liver Neoplasms / pathology. Liver Neoplasms / radiography. Liver Neoplasms / secondary. Lymphatic Metastasis / pathology. Lymphatic Metastasis / radiography. Male. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20847536.001).
  • [ISSN] 1349-6867
  • [Journal-full-title] The journal of medical investigation : JMI
  • [ISO-abbreviation] J. Med. Invest.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


3. Park JS, Kim L, Kim CH, Bang BW, Lee DH, Jeong S, Shin YW, Kim HG: Synchronous large-cell neuroendocrine carcinoma and adenocarcinoma of the colon. Gut Liver; 2010 Mar;4(1):122-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Synchronous large-cell neuroendocrine carcinoma and adenocarcinoma of the colon.
  • In addition, the tumor of the cecum showed microscopic findings consistent with a well-differentiated adenocarcinoma.
  • Postoperative chemotherapy was applied.
  • This is the first case of a synchronous large-cell neuroendocrine carcinoma and adenocarcinoma of the colon.
  • The patient was treated successfully with debulking surgery and systemic chemotherapy.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Rev Esp Enferm Dig. 2008 Jan;100(1):11-6 [18358055.001]
  • [Cites] Int J Colorectal Dis. 2008 Mar;23(3):325-7 [18064472.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Aug;19(4):553-76 [16183527.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Aug;19(4):491-505 [16183523.001]
  • [Cites] Pathol Int. 2005 Aug;55(8):524-9 [15998383.001]
  • [Cites] Gynecol Oncol. 2001 Jul;82(1):187-91 [11426984.001]
  • [Cites] Surgery. 1994 Jun;115(6):762-6 [8197570.001]
  • [Cites] Ann N Y Acad Sci. 2004 Apr;1014:13-27 [15153416.001]
  • [Cites] Anticancer Res. 2004 Mar-Apr;24(2C):1049-51 [15154621.001]
  • [Cites] Virchows Arch. 2002 Sep;441(3):256-63 [12242522.001]
  • [Cites] Cancer Res. 1994 Jul 1;54(13):3500-5 [8012973.001]
  • (PMID = 20479925.001).
  • [ISSN] 2005-1212
  • [Journal-full-title] Gut and liver
  • [ISO-abbreviation] Gut Liver
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Korea (South)
  • [Other-IDs] NLM/ PMC2871610
  • [Keywords] NOTNLM ; Chemotherapy / Colonic neoplasms / Multiple primary neoplasms / Neuroendocrine carcinoma
  •  go-up   go-down


Advertisement
4. Shiba Y, Umekita N, Noda K, Kitamura M: [A case report of recurrence of liver metastases from colorectal cancer, which seemed to have vanished for a time by intra-aortic chemotherapy]. Gan To Kagaku Ryoho; 2005 Oct;32(11):1829-31
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case report of recurrence of liver metastases from colorectal cancer, which seemed to have vanished for a time by intra-aortic chemotherapy].
  • The diagnosis was Stage IV well-differentiated tubular adeno carcinoma. n1H3M(-).
  • As adjuvant chemotherapy, we chose intra-arterial infusion of 5-FU 1,500 mg/body/week from July 2002 to February 2003.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Antimetabolites, Antineoplastic / administration & dosage. Colorectal Neoplasms / pathology. Fluorouracil / administration & dosage. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary
  • [MeSH-minor] Aged. Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Combined Modality Therapy. Hepatectomy. Humans. Infusions, Intra-Arterial. Male. Neoplasm Recurrence, Local

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16315954.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 7673326042 / irinotecan; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


5. Wang HJ, Zhu JS, Zhang Q, Sun Q, Guo H: High level of ezrin expression in colorectal cancer tissues is closely related to tumor malignancy. World J Gastroenterol; 2009 Apr 28;15(16):2016-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] High level of ezrin expression in colorectal cancer tissues is closely related to tumor malignancy.
  • AIM: To investigate the ezrin expression in normal colorectal mucosa and colorectal cancer tissues, and study the correlation between ezrin expression in colorectal cancer tissues and tumor invasion and metastasis.
  • METHODS: Eighty paraffin-embedded cancer tissue samples were selected from primary colorectal adenocarcinoma.
  • Twenty-eight patients had well-differentiated, 22 had moderately differentiated and 30 had poorly differentiated adenocarcinoma.
  • Another 22 paraffin-embedded tissue blocks of normal colorectal epithelium (> 5 cm away from the edge of the tumor) were selected as the control group.
  • All patients with colorectal cancer were treated surgically and diagnosed histologically, without preoperative chemotherapy or radiotherapy.
  • The immunohistochemistry was used to detect the ezrin expression in paraffin-embedded normal colorectal mucosa tissues and colorectal cancer tissue samples.
  • RESULTS: Ezrin expression in colorectal cancer was significantly higher than in normal colorectal mucosa (75.00% vs 9.09%, P < 0.01), and there was a close relationship between ezrin expression and the degree of tumor differentiation, lymph node metastasis and Dukes stage (88.46% vs 50.00%, P < 0.01; 94.28% vs 51.11%, P < 0.01; 94.28% vs 51.11%, P < 0.01).
  • CONCLUSION: Ezrin expression is obviously higher in colorectal cancer tissues than in normal colorectal mucosa tissues, and the high level of ezrin expression is closely related to the colorectal cancer invasion and metastasis process.
  • [MeSH-major] Colorectal Neoplasms. Cytoskeletal Proteins / metabolism. Neoplasm Invasiveness / pathology

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2001 May 1;61(9):3750-9 [11325848.001]
  • [Cites] Maturitas. 2008 May 20;60(1):31-41 [18486367.001]
  • [Cites] Gynecol Oncol. 2003 Aug;90(2):273-81 [12893187.001]
  • [Cites] Nat Rev Cancer. 2003 Nov;3(11):877-83 [14668818.001]
  • [Cites] Microvasc Res. 2004 Jan;67(1):18-28 [14709399.001]
  • [Cites] Gut. 2004 Feb;53(2):235-40 [14724156.001]
  • [Cites] Nat Med. 2004 Feb;10(2):175-81 [14704789.001]
  • [Cites] Nat Med. 2004 Feb;10(2):182-6 [14704791.001]
  • [Cites] Cancer Cell. 2004 Feb;5(2):113-4 [14998486.001]
  • [Cites] Urology. 2004 Mar;63(3):609-12 [15028477.001]
  • [Cites] Trends Mol Med. 2004 May;10(5):201-4 [15121044.001]
  • [Cites] Trends Mol Med. 2004 Jun;10(6):249-50 [15177187.001]
  • [Cites] J Cell Biol. 1994 Jul;126(2):391-401 [7518464.001]
  • [Cites] J Biol Chem. 1996 Mar 22;271(12):7224-9 [8636161.001]
  • [Cites] J Pathol. 1996 May;179(1):74-9 [8691349.001]
  • [Cites] Oncogene. 1996 Sep 19;13(6):1231-7 [8808697.001]
  • [Cites] EMBO J. 1997 Jan 2;16(1):35-43 [9009265.001]
  • [Cites] Trends Biochem Sci. 1996 Dec;21(12):455-8 [9009824.001]
  • [Cites] Curr Biol. 1997 Sep 1;7(9):682-8 [9285722.001]
  • [Cites] J Cell Biol. 1998 Feb 23;140(4):885-95 [9472040.001]
  • [Cites] Biochem Biophys Res Commun. 1999 May 10;258(2):395-400 [10329398.001]
  • [Cites] Breast Cancer Res. 2005;7(3):R365-73 [15987432.001]
  • [Cites] Apoptosis. 2005 Oct;10(5):941-7 [16151629.001]
  • [Cites] Cancer Res. 2006 Apr 1;66(7):3629-38 [16585188.001]
  • [Cites] Infect Immun. 2007 Dec;75(12):5669-77 [17908813.001]
  • [Cites] Cancer Lett. 2008 Mar 8;261(1):55-63 [18155831.001]
  • [Cites] Ai Zheng. 2008 Feb;27(2):165-9 [18279614.001]
  • [Cites] J Cell Sci. 2008 Mar 1;121(Pt 5):644-54 [18270268.001]
  • [Cites] Pediatr Blood Cancer. 2008 Apr;50(4):752-6 [17886294.001]
  • [Cites] Pol J Pathol. 2007;58(4):235-43 [18459457.001]
  • [Cites] Mol Biol Cell. 2003 May;14(5):2181-91 [12802084.001]
  • (PMID = 19399936.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Cytoskeletal Proteins; 0 / ezrin
  • [Other-IDs] NLM/ PMC2675094
  •  go-up   go-down


6. Nozoe Y, Ogata Y, Miyagi Y, Nakagawa M, Matono K, Sasatomi T, Araki Y, Shirouzu K: [Efficacy of postoperative adjuvant chemotherapy for colorectal cancer]. Gan To Kagaku Ryoho; 2002 Jan;29(1):67-72
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of postoperative adjuvant chemotherapy for colorectal cancer].
  • We attempted postoperative adjuvant chemotherapy for stage II or III colorectal cancer.
  • To investigate the efficacy of the adjuvant chemotherapy, we retrospectively reviewed all 293 colorectal cancer patients who underwent curative resection between 1990 and 1996 in Kurume University Hospital.
  • The patients were divided into two groups according to whether or not they received postoperative adjuvant chemotherapy.
  • Findings were similar between the two groups for those with stage II, stage IIIa, a low grade of lymphatic and venous invasion, and well-differentiated adenocarcinoma.
  • Postoperative adjuvant chemotherapy in colorectal cancer might reduce the risk of recurrence, particularly in cases of rectal cancer.
  • However, postoperative adjuvant chemotherapy was insufficient for those with highly advanced cancer or a biologically aggressive tumor.
  • [MeSH-major] Colonic Neoplasms / drug therapy. Rectal Neoplasms / drug therapy
  • [MeSH-minor] Aged. Antibiotics, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / administration & dosage. Chemotherapy, Adjuvant. Female. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Mitomycin / administration & dosage. Postoperative Care. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11816480.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 0 / Antimetabolites, Antineoplastic; 50SG953SK6 / Mitomycin; U3P01618RT / Fluorouracil
  •  go-up   go-down


7. Yamada T, Tanaka N, Yokoi K, Seya T, Kanazawa Y, Koizumi M, Ohaki Y, Tajiri T: Correlation between clinical pathologic factors and activity of 5-FU-metabolizing enzymes in colorectal cancer. J Nippon Med Sch; 2008 Feb;75(1):23-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Correlation between clinical pathologic factors and activity of 5-FU-metabolizing enzymes in colorectal cancer.
  • The expression levels and activities of these three enzymes play important roles in the response of cancer patients to 5-FU-based chemotherapy.
  • PURPOSE: The purpose of this study was to investigate the relationship between the activities of 5-FU metabolic enzymes and clinicopathologic factors in colorectal cancer.
  • METHODS: We measured the activities of OPRT, DPD, and TS in colorectal cancer tissues.
  • We also investigated the correlations between the activities of these three enzymes and clinicopathologic factors (histological type, depth of tumor invasion, extent of lymph node metastasis, Dukes' stage, lymphatic invasion, and vascular invasion).
  • We examined 100 patients with surgically resected colorectal cancer.
  • RESULTS: Poorly differentiated adenocarcinoma showed significantly higher DPD activities than did moderately differentiated or well-differentiated adenocarcinoma.
  • No significant relation was found between TS activity and histological type, depth of tumor invasion, extent of lymph node metastasis, Dukes' stage, lymphatic invasion, or vascular invasion.
  • CONCLUSION: The response to 5-FU may be poor in patients with lymph-node metastasis, because of low OPRT activity, and in patients with poorly differentiated adenocarcinoma, because of high DPD activity.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / enzymology. Antimetabolites, Antineoplastic / therapeutic use. Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / enzymology. Fluorouracil / metabolism. Fluorouracil / therapeutic use. Orotate Phosphoribosyltransferase / metabolism

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18360075.001).
  • [ISSN] 1345-4676
  • [Journal-full-title] Journal of Nippon Medical School = Nippon Ika Daigaku zasshi
  • [ISO-abbreviation] J Nippon Med Sch
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; EC 1.3.1.2 / Dihydrouracil Dehydrogenase (NADP); EC 2.1.1.45 / Thymidylate Synthase; EC 2.4.2.10 / Orotate Phosphoribosyltransferase; U3P01618RT / Fluorouracil
  •  go-up   go-down


8. Kubo H, Miki C, Kusunoki M: Evaluation of genetic mutations of tumor suppresser genes in colorectal cancer patients. Hepatogastroenterology; 2004 Jan-Feb;51(55):114-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of genetic mutations of tumor suppresser genes in colorectal cancer patients.
  • BACKGROUND/AIMS: The mutation of tumor suppresser genes of colorectal cancer was evaluated to clarify its significance in the clinical management of colorectal cancer patients.
  • METHODOLOGY: Polymerase chain reaction amplification was performed to investigate the loss of heterozygosity (LOH) of the DCC (deleted-in-colorectal-carcinoma) gene and p53 gene in 76 colorectal cancers.
  • Moreover, younger patients and patients with a well-differentiated adenocarcinoma had a higher risk of liver and lymph node metastasis when the tumor had DCC LOH.
  • CONCLUSIONS: The careful exploration of the liver and regional lymph nodes is advocated when the tumor has a DCC alteration, even at an early stage of the disease and especially in younger patients and patients with a well-differentiated carcinoma.
  • The assessment of DCC LOH may be useful for selecting patients for extensive surgical intervention or adjuvant chemotherapy.
  • [MeSH-major] Colorectal Neoplasms / genetics. Genes, DCC / genetics. Loss of Heterozygosity. Tumor Suppressor Protein p53 / genetics

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15011843.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


9. Kravarusic D, Feigin E, Dlugy E, Steinberg R, Baazov A, Erez I, Lazar L, Kapuller V, Grunspan M, Ash S, Freud E: Colorectal carcinoma in childhood: a retrospective multicenter study. J Pediatr Gastroenterol Nutr; 2007 Feb;44(2):209-11
MedlinePlus Health Information. consumer health - Colorectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Colorectal carcinoma in childhood: a retrospective multicenter study.
  • OBJECTIVES: Colorectal carcinoma, a common adult malignancy, has an estimated childhood incidence of 0.3 to 1.5/million in Western countries and 0.2/million in Israel.
  • The aim of this multicenter study was to document the clinical profile, treatment and prognosis of colorectal carcinoma in children in Israel.
  • PATIENTS AND METHODS: The clinical, laboratory, therapeutic, and prognostic parameters of all 7 children from 4 medical centers in Israel who were diagnosed with colorectal carcinoma over a 25-y period were reviewed.
  • Average time to diagnosis was 6 months.
  • Six patients underwent surgery (1 refused), and 5 received chemotherapy.
  • Histopathological studies showed poorly differentiated mucinous adenocarcinoma, signet-ring type, in 4 cases, moderately differentiated adenocarcinoma in 2, and well-differentiated carcinoma in 1.
  • CONCLUSION: Colorectal carcinoma in children is characterized by aggressive tumor behavior and delayed diagnosis, resulting in a worse prognosis than in adults.
  • [MeSH-major] Adenocarcinoma / diagnosis. Adenocarcinoma / therapy. Colorectal Neoplasms / diagnosis. Colorectal Neoplasms / therapy
  • [MeSH-minor] Adolescent. Antineoplastic Agents / therapeutic use. Child, Preschool. Colectomy. Female. Humans. Israel. Male. Prognosis. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17255833.001).
  • [ISSN] 1536-4801
  • [Journal-full-title] Journal of pediatric gastroenterology and nutrition
  • [ISO-abbreviation] J. Pediatr. Gastroenterol. Nutr.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


10. Bruin SC, Verwaal VJ, Vincent A, van't Veer LJ, van Velthuysen ML: A clinicopathologic analysis of peritoneal metastases of colorectal and appendiceal origin. Ann Surg Oncol; 2010 Sep;17(9):2330-40
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A clinicopathologic analysis of peritoneal metastases of colorectal and appendiceal origin.
  • OBJECTIVE: To predict clinical outcome by classification of peritoneal metastases (PM) of colorectal or appendiceal origin.
  • BACKGROUND: This study investigates whether standardized histological classification can predict outcome for PM of colorectal or appendiceal origin treated with cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC).
  • Covariates included tumor, patient, and treatment characteristics.
  • RESULTS: PM could be categorized into four groups: low-grade, well-differentiated mucinous tumor (DPAM); intermediated-grade mucinous carcinoma (PMCA-i); high-grade mucinous carcinoma (PMCA); and high-grade nonmucinous carcinoma (PCA).
  • Multivariate analysis showed that histological classification, gender, number of segments affected, completeness of cytoreduction, and HIPEC as primary treatment were significant related to OS and DFS.
  • Of PM originating from an appendix tumor, 29% were of non-DPAM type.
  • Of primary colorectal tumors, 37% resulted in mucinous PM, and another 26% of PM of colorectal origin had partly mucinous histology.
  • Low-grade PM (DPAM) should be regarded as a separate entity because of its clearly different clinical course.
  • High-grade mucinous PM has significant better prognosis than nonmucinous PM and should thus be distinguished.
  • [MeSH-major] Adenocarcinoma, Mucinous / secondary. Appendiceal Neoplasms / pathology. Colorectal Neoplasms / pathology. Peritoneal Neoplasms / secondary
  • [MeSH-minor] Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Survival Rate

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20232161.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


11. Franceschi F, Fini L, Manno A, Carloni E, Zocco MA, Di Caro S, Picciocchi A, Coco C, Gasbarrini G, Gasbarrini A: Gene-expression profile of colorectal adenocarcinoma tissues identified by gene microarray analysis. J Clin Oncol; 2004 Jul 15;22(14_suppl):3651

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene-expression profile of colorectal adenocarcinoma tissues identified by gene microarray analysis.
  • : 3651 Background: Several genes are differentially expressed during the multistep process of colorectal carcinogenesis.
  • Aim of the study was to identify the gene expression of colorectal adenocarcinoma tissues compared to the normal mucosa.
  • METHODS: RNA was extracted from 3 samples of moderately differentiated sporadic rectal adenocarcinoma and 3 samples of normal rectal mucosa obtained from the same patients and hybridized against the human U133A array set.
  • Gene expression of tumoral tissues and normal samples was compared; a minimum of 3 times fold differential expression among the same genes in neoplastic and normal samples was considered as significant.
  • Real-time PCR (Roche, Manheim) using the same RNA was also performed on a pool of either up- or down-regulated randomly-selected genes to validate the results.
  • 537 genes were upregulated while 13 genes were downregulated in neoplastic tissues.
  • The up-regulated genes included angiogenic factors (VEGF, PD-ECGF, EGF), markers of proliferation (PCNA), tumoral markers (CEA, ACE), genes involved in chemotherapy activity (Farnesyl-transferase, Topoisomerase-1) and several other genes of unclear function.
  • CONCLUSIONS: Colorectal cancer tissues show a different gene expression compared to the normal mucosa.
  • This differential expression includes several known genes involved in cell growth, angiogenesis, transcription and proliferation as well as other genes of unclear activity, which have never previously been associated with cancer.
  • The identification of a panel of genes specifically expressed in neoplastic tisssues may provide a new tool for the molecular diagnosis of colorectal cancer and furnish new molecular targets for innovative therapeutical strategies.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 28014587.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


12. Chen WY, Mao WM, Zhao L, Chen GP, Shu Y, Shen YF, Zhu XH, Xia Y: [Expression of P-gp, GST-pi and Topo II alpha in gastric and colorectal cancers and their clinical significance]. Zhonghua Zhong Liu Za Zhi; 2005 Dec;27(12):738-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Expression of P-gp, GST-pi and Topo II alpha in gastric and colorectal cancers and their clinical significance].
  • OBJECTIVE: To study the expression and clinical significance of P-gp, GST-pi and Topo II alpha in gastric and colorectal cancers.
  • METHODS: The expression of P-gp, GST-pi and Topo II alpha in 83 cases with gastric or colorectal cancer were examined by immunohistochemistry S-P.
  • RESULTS: The positive expression rates of P-gp, GST-pi, Topo II alpha in normal tissue and gastric and colorectal cancers were 69.9%, 65.1%, 50.6% and 83.1%, 85.5%, 45.8%, respectively.
  • The positive rates of P-gp and GST-pi in gastric and colorectal cancer were significantly higher than those in normal gastric and colorectal tissue (P < 0.05).
  • The expression of Topo II alpha in poorly differentiated cancers was significantly higher than that in well-and moderately differentiated cancers.
  • Their mechanisms of drug resistance were different.
  • The detection of expression of P-gp, GST-pi and Topo II alpha has an important guiding significance in chemotherapy for gastric and colorectal cancers.
  • [MeSH-major] Antigens, Neoplasm / biosynthesis. DNA Topoisomerases, Type II / biosynthesis. DNA-Binding Proteins / biosynthesis. Drug Resistance, Neoplasm. Gastrointestinal Neoplasms / metabolism. Glutathione S-Transferase pi / biosynthesis. P-Glycoprotein / biosynthesis
  • [MeSH-minor] Adenocarcinoma / metabolism. Adult. Aged. Aged, 80 and over. Colorectal Neoplasms / metabolism. Female. Humans. Immunohistochemistry. Male. Middle Aged. Stomach Neoplasms / metabolism

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16483485.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / DNA-Binding Proteins; 0 / P-Glycoprotein; EC 2.5.1.18 / Glutathione S-Transferase pi; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


13. Katsumata K, Ichimiya H, Wakana Y, Okada K, Kato K, Aoki T: [Case report of two colorectal cancer patients with liver metastasis showing favorable response to fluorouracil and l-leucovorin therapy]. Gan To Kagaku Ryoho; 2004 Apr;31(4):623-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Case report of two colorectal cancer patients with liver metastasis showing favorable response to fluorouracil and l-leucovorin therapy].
  • We treated 2 patients with colorectal cancer accompanied by liver metastasis who showed favorable response to combined treatment with fluorouracil and l-Leucovorin.
  • Case 1 was a 40-year-old man with rectal carcinoma (moderately differentiated adenocarcinoma; se, n1, p1, H0, stage IV).
  • He underwent low anterior resection of the rectum and postoperatively showed an increase peritoneal dissemination and liver metastasis.
  • At course 3, the liver metastasis showed partial response and, during the 18 months after the 7th course, his peritoneal dissemination and other lesions were well controlled.
  • As of 30 months post-treatment the patient was alive.
  • Case 2 was a 60-year-old man with rectal carcinoma (well differentiated adenocarcinoma; ss, n1, p0, H1, stage IV).
  • He underwent low anterior resection and postoperatively was given 3 courses of fluorouracil and l-Leucovorin.
  • Adverse drug reactions in both patients were controlled on an outpatient basis.
  • While in the past liver metastasis has been treated by hepatic arterial infusion chemotherapy, a combination therapy with fluorouracil and l-Leucovorin can be used on an outpatient basis and results in a favorable response.
  • This suggests that this combination therapy has clinical significance.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / secondary. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Rectal Neoplasms / drug therapy
  • [MeSH-minor] Adult. Drug Administration Schedule. Fluorouracil / administration & dosage. Hepatic Artery. Humans. Infusions, Intra-Arterial. Leucovorin / administration & dosage. Male. Middle Aged. Peritoneal Neoplasms / secondary

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15114713.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


14. Yaacob NS, Darus HM, Norazmi MN: Modulation of cell growth and PPARgamma expression in human colorectal cancer cell lines by ciglitazone. Exp Toxicol Pathol; 2008 Sep;60(6):505-12
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modulation of cell growth and PPARgamma expression in human colorectal cancer cell lines by ciglitazone.
  • The present study was performed to investigate the effects of the PPARgamma ligand, ciglitazone, and the involvement of PPARgamma in modulating the growth of human colorectal cancer cells.
  • Lactate dehydrogenase release assay showed that ciglitazone potently inhibited HT-29 (well-differentiated) and COLO-205 (poorly differentiated) colorectal adenocarcinoma cell growth.
  • Measurement of apoptosis by flow cytometry using a fluorescein-conjugated monoclonal antibody against cytokeratin 18 revealed a high induction of apoptosis by ciglitazone in a time-dependent fashion.
  • The expression of PPARgamma1 but not PPARgamma2 mRNA was significantly downregulated as measured by real-time quantitative PCR, and the PPARgamma protein levels were decreased as determined by Western blot analysis.
  • We conclude that ciglitazone treatment suppressed colon cancer cell growth via induction of apoptosis.
  • [MeSH-major] Adenocarcinoma / drug therapy. Colorectal Neoplasms / drug therapy. Gene Expression Regulation, Neoplastic / drug effects. Hypoglycemic Agents / pharmacology. PPAR gamma / genetics. Thiazolidinediones / pharmacology
  • [MeSH-minor] Apoptosis / drug effects. Cell Line, Tumor. Cell Survival / drug effects. Down-Regulation. Drug Screening Assays, Antitumor. Humans. L-Lactate Dehydrogenase / metabolism

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Diabetes Medicines.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18579355.001).
  • [ISSN] 0940-2993
  • [Journal-full-title] Experimental and toxicologic pathology : official journal of the Gesellschaft für Toxikologische Pathologie
  • [ISO-abbreviation] Exp. Toxicol. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Hypoglycemic Agents; 0 / PPAR gamma; 0 / Thiazolidinediones; 74772-77-3 / ciglitazone; EC 1.1.1.27 / L-Lactate Dehydrogenase
  •  go-up   go-down


15. Li LN, Zhang HD, Yuan SJ, Yang DX, Wang L, Sun ZX: Differential sensitivity of colorectal cancer cell lines to artesunate is associated with expression of beta-catenin and E-cadherin. Eur J Pharmacol; 2008 Jun 24;588(1):1-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differential sensitivity of colorectal cancer cell lines to artesunate is associated with expression of beta-catenin and E-cadherin.
  • In the present investigation, we compared the anticancer effects of artesunate on three colorectal cancer cell lines and analyzed the relationship between drug sensitivity and malignant phenotype of the tumor cells.
  • The findings are as follows: poorly-differentiated was colorectal cancer cell line CLY showing nuclear beta-catenin accumulation and loss of E-cadherin; moderately-differentiated were Lovo cells with cytoplasmic distribution of the two proteins; and well-differentiated were HT-29 cells with membranous localization of them.
  • Also, both in vitro and in vivo, poorly- or moderately-differentiated CLY and Lovo were more susceptible to artesunate treatment than well-differentiated HT-29.
  • Due to the vital roles of Wnt pathway and the epithelial to mesenchymal transition in tumor differentiation, we thought artesunate could promote the re-differentiation and apoptosis of colorectal cancer cells by inhibition of hyperactive Wnt pathway and reversion of the epithelial to mesenchymal transition.
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / metabolism. Antineoplastic Agents. Artemisinins / pharmacology. Cadherins / biosynthesis. Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / metabolism. beta Catenin / biosynthesis
  • [MeSH-minor] Animals. Apoptosis / drug effects. Blotting, Western. Cell Cycle / drug effects. Cell Differentiation / drug effects. Cell Line, Tumor. Cell Proliferation / drug effects. Female. Flow Cytometry. Fluorescent Antibody Technique, Indirect. Humans. Immunohistochemistry. Male. Mice. Mice, Inbred BALB C. Mice, Nude. Middle Aged. Neoplasm Proteins / biosynthesis. Subcellular Fractions / drug effects

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18448095.001).
  • [ISSN] 0014-2999
  • [Journal-full-title] European journal of pharmacology
  • [ISO-abbreviation] Eur. J. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Artemisinins; 0 / Cadherins; 0 / Neoplasm Proteins; 0 / beta Catenin; 60W3249T9M / artesunate
  •  go-up   go-down


16. Seront E, Marot L, Coche E, Gala JL, Sempoux C, Humblet Y: Successful long-term management of a patient with late-stage metastatic colorectal cancer treated with panitumumab. Cancer Treat Rev; 2010 Feb;36 Suppl 1:S11-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Successful long-term management of a patient with late-stage metastatic colorectal cancer treated with panitumumab.
  • INTRODUCTION: Recent approval and introduction into clinical practice of epidermal growth factor receptor inhibitors such as the chimeric monoclonal antibody cetuximab and the fully human monoclonal antibody panitumumab have provided new treatment options for chemotherapy-refractory patients.
  • Here, we report a case of a 47-year-old man with metastatic, chemotherapy-refractory colorectal cancer who achieved long-term partial remission during panitumumab therapy.
  • A computed tomography (CT) scan revealed a voluminous and perforated abscess with a suspected tumour lesion in the sigmoid colon.
  • The patient underwent sigmoidectomy and was diagnosed with a poorly differentiated necrotic carcinoma of the sigmoid colon with invasion in 13 of 19 tested lymph nodes.
  • A colonoscopy revealed multiple tubular adenomas and a positron emission tomography CT scan showed multiple and bilateral hyperfixating lumbar-aortic lymph nodes leading to a final tumour classification of T4N2M1.
  • The patient achieved a partial response following six cycles of FOLFIRI (irinotecan, 5-fluorouracil, leucovorin), then progressed and was enrolled in a trial where he received treatment with FOLFOX4 (oxaliplatin, leucovorin and 5-fluorouracil) with or without a vascular endothelial growth factor inhibitor (PTK787/ZK 222584 [valatinib]).
  • A partial response was noted after 8 weeks of therapy along with a rapid CEA reduction and decrease in lymph node size.
  • The patient is continuing panitumumab treatment and is still in partial remission after 65 months' treatment.
  • During treatment the patient has on occasion experienced grade 1-2 diarrhoea as well as folliculitis and acne-like rash up to grade 3 in severity.
  • CONCLUSION: This case shows that long-term responses are possible during panitumumab therapy and that this agent may be an effective long-term treatment option for selected patients with metastatic colorectal cancer.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Colorectal Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Camptothecin / therapeutic use. Clinical Trials as Topic. Diarrhea / chemically induced. Exanthema / chemically induced. Fluorouracil / therapeutic use. Folliculitis / chemically induced. Humans. Leucovorin / therapeutic use. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Staging. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • Genetic Alliance. consumer health - Metastatic cancer.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. LEUCOVORIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Cancer Treat Rev. 2010 Feb;36 Suppl 1:S15-6 [20189055.001]
  • (PMID = 20189054.001).
  • [ISSN] 1532-1967
  • [Journal-full-title] Cancer treatment reviews
  • [ISO-abbreviation] Cancer Treat. Rev.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antineoplastic Agents; 0 / panitumumab; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; XT3Z54Z28A / Camptothecin; IFL protocol
  •  go-up   go-down


17. Aranda E, Abad A, Carrato A, Cervantes A, Tabernero J, Díaz-Rubio E, TTD Group: Guides for adjuvant treatment of colon cancer. TTD Group (Spanish Cooperative Group for Gastrointestinal Tumor Therapy). Clin Transl Oncol; 2006 Feb;8(2):98-102
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Guides for adjuvant treatment of colon cancer. TTD Group (Spanish Cooperative Group for Gastrointestinal Tumor Therapy).
  • The choice of the most suitable chemotherapy schedule for the adjuvant treatment of colon cancer has been reviewed by the TTD group, as well as the principles of risk assessment for patients with stage II disease.
  • In patients with stage II disease, the indication of chemotherapy must be individualized and based on the patient's risk of recurrence (perforation, obstruction, peritumoral lymphovascular involvement, poorly differentiated histology, number of lymph nodes examined < or = 11, pre-surgical CEA), and comorbidities that can compromise the safety of treatment or survival of the patient.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Colorectal Neoplasms / drug therapy
  • [MeSH-minor] Adenocarcinoma / drug therapy. Adenocarcinoma / pathology. Adenocarcinoma / surgery. Algorithms. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / therapeutic use. Capecitabine. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Drug Administration Schedule. Fluorouracil / administration & dosage. Humans. Leucovorin / administration & dosage. Lymphatic Metastasis. Neoplasm Staging. Organoplatinum Compounds / administration & dosage. Randomized Controlled Trials as Topic. Risk Assessment. Tegafur / administration & dosage. Uracil / administration & dosage

  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 May;17(5):1349-55 [10334518.001]
  • [Cites] Clin Colorectal Cancer. 2005 Mar;4(6):384-9 [15807931.001]
  • [Cites] J Clin Oncol. 1995 Dec;13(12):2936-43 [8523058.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):1797-806 [15067028.001]
  • [Cites] J Clin Oncol. 2003 Aug 1;21(15):2896-903 [12885807.001]
  • [Cites] J Clin Oncol. 1999 May;17(5):1356-63 [10334519.001]
  • [Cites] J Clin Oncol. 2005 Dec 1;23(34):8664-70 [16260700.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3395-407 [15199087.001]
  • [Cites] J Clin Oncol. 2004 Aug 15;22(16):3408-19 [15199089.001]
  • [Cites] Ann Oncol. 2009 Apr;20(4):674-80 [19179549.001]
  • [Cites] Br J Cancer. 2001 Nov 16;85(10):1437-43 [11720425.001]
  • [Cites] N Engl J Med. 2004 Jun 3;350(23):2343-51 [15175436.001]
  • [Cites] Ann Oncol. 2003;14 Suppl 5:v61-118 [14684501.001]
  • (PMID = 16632423.001).
  • [ISSN] 1699-048X
  • [Journal-full-title] Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  • [ISO-abbreviation] Clin Transl Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Practice Guideline
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Organoplatinum Compounds; 04ZR38536J / oxaliplatin; 0W860991D6 / Deoxycytidine; 1548R74NSZ / Tegafur; 56HH86ZVCT / Uracil; 6804DJ8Z9U / Capecitabine; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil; 1-UFT protocol; Folfox protocol
  •  go-up   go-down


18. Noura S, Ohue M, Murata K, Kameyama M, Kishi K, Takachi K, Eguchi H, Yamada T, Miyashiro I, Yano M, Ohigashi H, Sasaki Y, Ishikawa O, Imaoka S: [A case of high-dose rate interstitial brachytherapy for locally recurrent rectal cancer]. Gan To Kagaku Ryoho; 2006 Nov;33(12):1801-3
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumor was a well differentiated adenocarcinoma, type 2 in the Japanese classification of colorectal carcinoma, and was measured 2.3 cm in size.
  • She received adjuvant chemotherapy with 5'-DFUR.
  • After 13 months from the surgery, the patient developed a hip pain.
  • Biopsy from the tumor revealed adenocarcinoma.
  • Chemotherapy with CPT-11 (230 mg/body) and 5'-DFUR (800 mg/body) was administered for 2 cycles.
  • Because the tumor was enlarged, high-dose rate interstitial brachytherapy was given to the recurrent site at a total dose of 54 Gy/9 fractions/5 days.
  • [MeSH-major] Adenocarcinoma / radiotherapy. Brachytherapy. Rectal Neoplasms / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17212112.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen
  •  go-up   go-down


19. Yoshitani S, Imaizumi H, Kuroda M, Yokoi M, Tanaka Y, Harada H, Kosaka T, Takashima S: [A case of long-term survival after chemo-radiation for postoperative local recurrence of rectal cancer]. Gan To Kagaku Ryoho; 2004 Oct;31(11):1867-9
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The tumor was a well-differentiated adenocarcinoma, type 2 in the Japanese Classification of Colorectal Carcinoma, and was measured 5.5x4.3 cm in size.
  • He received a postoperative chemotherapy with oral UFT-E (400 mg/day) for 1 year.
  • After 2 years from the surgery, the patient developed a perineal pain, and pelvic CT scans revealed a 4 cm mass anterior to the sacrum.
  • Radiotherapy was given to the pelvic region at a total dose of 70 Gy (Given 2 Gy each x 35 fragments).
  • Chemotherapy with CDDP and 5-FU was administered via the right internal iliac artery followed by administration of 5'-DFUR (600 mg/day).
  • After that regimen, a recurrence of the pelvic tumor caused an increase in pain, and the patient developed renal failure.
  • He died after 4 years and 10 months from the initial detection of recurrence.
  • This report presents a case of local recurrence of advanced rectal carcinoma, in which we were able to achieve a long-term survival and improvement in QOL by an intensive multidisciplinary therapy.
  • [MeSH-major] Adenocarcinoma / therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neoplasm Recurrence, Local / therapy. Rectal Neoplasms / therapy
  • [MeSH-minor] Cisplatin / administration & dosage. Combined Modality Therapy. Floxuridine / administration & dosage. Fluorouracil / administration & dosage. Humans. Male. Middle Aged. Radiotherapy Dosage

  • Genetic Alliance. consumer health - Rectal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLOXURIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15553742.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 039LU44I5M / Floxuridine; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; V1JK16Y2JP / doxifluridine
  •  go-up   go-down


20. Chintamani, Singhal V, Bansal A, Bhatnagar D, Saxena S: Isolated colostomy site recurrence in rectal cancer-two cases with review of literature. World J Surg Oncol; 2007;5:52
Genetic Alliance. consumer health - Rectal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Both patients had received adjuvant chemotherapy following surgery.
  • CASE PRESENTATION: First case was a 30-year-old male that had reported with large bowel obstruction due to an obstructing ulcero-proliferative growth (poorly differentiated adenocarcinoma) at the colostomy site after abdomino-perineal resection, performed for low rectal cancer six years previously.
  • Second case was a 47-year-old male that presented with acute large bowel obstruction due to an annular growth (well differentiated adenocarcinoma) in the upper rectum.
  • Five years following closure of colostomy, he presented with two parietal masses at the previous colostomy site scar, which, on fine needle aspiration cytology were found to be well-differentiated adenocarcinomas of colorectal type.
  • [MeSH-major] Adenocarcinoma / pathology. Colostomy / adverse effects. Neoplasms, Second Primary / pathology. Rectal Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Gastroenterol. 2002;37(5):387-90 [12051539.001]
  • [Cites] J Postgrad Med. 2003 Apr-Jun;49(2):157-8 [12867694.001]
  • [Cites] Gastroenterology. 1958 Jan;34(1):85-98 [13501357.001]
  • [Cites] Cancer. 1974 Jun;33(6):1630-4 [4834157.001]
  • [Cites] Dis Colon Rectum. 1983 Jan;26(1):50-2 [6822162.001]
  • [Cites] Dis Colon Rectum. 1966 Nov-Dec;9(6):441-6 [5926156.001]
  • (PMID = 17567928.001).
  • [ISSN] 1477-7819
  • [Journal-full-title] World journal of surgical oncology
  • [ISO-abbreviation] World J Surg Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] England
  • [Number-of-references] 10
  • [Other-IDs] NLM/ PMC1876234
  • [General-notes] NLM/ Original DateCompleted: 20070730
  •  go-up   go-down


21. Shimizu T, Shigemasa Y, Kajiwara K, Sasaki N, Ikari H, Kunizaki T, Yonemitsu N: [A case of radiation therapy successfully treated liver and lung tumors arising from postoperative cecum cancer]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2149-51
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of radiation therapy successfully treated liver and lung tumors arising from postoperative cecum cancer].
  • The tumor was a well differentiated adenocarcinoma, type 2 in the Japanese classification of colorectal carcinoma.
  • He did not receive any adjuvant chemotherapy.
  • The patient refused both surgery and radio-frequency ablation therapy.
  • He was given a total dose of 50 Gy/25 fractions.
  • He was given a total dose of 66 Gy/33 fractions.
  • If the case was made a good choice, radiation therapy appears to be effective for liver and lung tumors from the colorectal cancer.
  • [MeSH-major] Adenocarcinoma / surgery. Cecal Neoplasms / surgery. Liver Neoplasms / radiotherapy. Liver Neoplasms / secondary. Lung Neoplasms / radiotherapy. Lung Neoplasms / secondary
  • [MeSH-minor] Aged, 80 and over. Colectomy. Humans. Male. Radiotherapy Dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Liver cancer.
  • Genetic Alliance. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037352.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


22. Handa R, Kato T, Miyake Y, Oshima K, Oshima S, Iijima S, Yamamoto H, Kurokawa E, Kikkawa N: [A long term survival case of advanced colon cancer with adjacent organ involvement and multiple liver metastases]. Gan To Kagaku Ryoho; 2006 Nov;33(12):1795-7
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histopathologically, it was a moderately differentiated adenocarcinoma with a biopsy examination.
  • The patient was followed by 8 courses of adjuvant chemotherapy with 5-FU.
  • He has been doing well without any recurrence for five years and six months after the operation.
  • Usually the prognoses of Stage IV colorectal cancer patients are very unpleasant.
  • Even thougn a few patients with Stage IV colorectal cancer can be a long-term survivor after multiple operations, we need to consider carefully the indication of the operation and QOL for a Stage IV colorectal cancer patient.
  • [MeSH-major] Adenocarcinoma / secondary. Cecal Neoplasms / pathology. Liver Neoplasms / secondary
  • [MeSH-minor] Chemotherapy, Adjuvant. Colectomy. Fluorouracil / therapeutic use. Hepatectomy. Humans. Male. Middle Aged. Neoplasm Invasiveness. Neoplasm Staging. Survivors

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17212110.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] U3P01618RT / Fluorouracil
  •  go-up   go-down


23. Kaufman M, Mehrotra B, Limaye S, White S, Fuchs A, Lebowicz Y, Nissel-Horowitz S, Thomas A: EGFR expression in gallbladder carcinoma in North America. Int J Med Sci; 2008;5(5):285-91
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Increased epidermal growth factor receptor (EGF receptor) expression has been noted in various cancers and has become a useful target for therapeutic interventions.
  • Eight patients had poorly differentiated adenocarcinoma, six had moderately differentiated and two had well-differentiated tumors.
  • In this small series, there was a trend toward shorter survival and more poorly differentiated tumors in patients with greater intensity of EGFR expression.
  • CONCLUSION: In view of our observations confirming the over-expression of EGFR in our patient population in North America, and the recent success of EGFR targeted therapies in other solid tumors that over-express EGFR, it may now be appropriate to evaluate agents targeting this pathway either as single agents or in combination with standard chemotherapy.
  • [MeSH-major] Adenocarcinoma / metabolism. Gallbladder Neoplasms / metabolism. Receptor, Epidermal Growth Factor / metabolism
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Staging. North America. Receptor, ErbB-2 / metabolism. Survival Analysis

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Clin Oncol. 2000 Aug;23(4):425-8 [10955877.001]
  • [Cites] J Clin Oncol. 2008 May 1;26(13):2112-7 [18378567.001]
  • [Cites] Hepatogastroenterology. 2001 May-Jun;48(39):783-9 [11462924.001]
  • [Cites] Cancer Res. 2001 Oct 1;61(19):6971-6 [11585718.001]
  • [Cites] J Clin Oncol. 2001 Oct 15;19(20):4089-91 [11600613.001]
  • [Cites] Ann Oncol. 2001 Oct;12(10):1403-6 [11762811.001]
  • [Cites] Am J Clin Oncol. 2002 Feb;25(1):96-100 [11823707.001]
  • [Cites] Science. 2002 Dec 6;298(5600):1912-34 [12471243.001]
  • [Cites] Ai Zheng. 2003 Mar;22(3):262-5 [12654182.001]
  • [Cites] Am J Clin Oncol. 2003 Apr;26(2):174-7 [12714891.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2003;10(4):265-81 [14598145.001]
  • [Cites] Invest New Drugs. 2004 Apr;22(2):193-8 [14739669.001]
  • [Cites] Br J Cancer. 2004 Apr 19;90(8):1516-20 [15083178.001]
  • [Cites] Korean J Gastroenterol. 2005 Jan;45(1):52-9 [15665568.001]
  • [Cites] Jpn J Clin Oncol. 2005 Feb;35(2):68-73 [15709089.001]
  • [Cites] J Clin Oncol. 2005 Apr 10;23(11):2445-59 [15753456.001]
  • [Cites] J Pathol. 2005 Jul;206(3):356-65 [15892172.001]
  • [Cites] J Cell Biochem. 2006 Mar 1;97(4):724-34 [16229013.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):634-6 [16467552.001]
  • [Cites] Cancer Chemother Pharmacol. 2006 May;57(5):647-53 [16142487.001]
  • [Cites] Cancer. 2006 Mar 15;106(6):1339-46 [16475213.001]
  • [Cites] Clin Cancer Res. 2006 Mar 15;12(6):1680-5 [16551849.001]
  • [Cites] Am J Clin Oncol. 2006 Apr;29(2):127-31 [16601429.001]
  • [Cites] Oncologist. 2008 Apr;13(4):415-23 [18448556.001]
  • [Cites] Rev Recent Clin Trials. 2007 May;2(2):111-6 [18473995.001]
  • [Cites] Oncology. 2007;72(1-2):105-10 [18025804.001]
  • [Cites] Ann Oncol. 2004 May;15(5):765-9 [15111344.001]
  • [Cites] N Engl J Med. 2004 May 20;350(21):2129-39 [15118073.001]
  • [Cites] J Cancer Res Clin Oncol. 2004 Jun;130(6):346-50 [14997381.001]
  • [Cites] N Engl J Med. 2004 Jul 22;351(4):337-45 [15269313.001]
  • [Cites] Ann Oncol. 2004 Sep;15(9):1339-43 [15319238.001]
  • [Cites] Oncology. 1994 Sep-Oct;51(5):396-400 [8052479.001]
  • [Cites] Eur J Cancer. 1995 Sep;31A(10):1594-8 [7488407.001]
  • [Cites] Pathol Res Pract. 1995 Nov;191(11):1087-91 [8822109.001]
  • [Cites] Ann Oncol. 1996 Aug;7(6):593-600 [8879373.001]
  • [Cites] J Clin Oncol. 1997 Jun;15(6):2403-13 [9196156.001]
  • [Cites] Cancer. 1998 Jun 15;82(12):2321-5 [9635523.001]
  • [Cites] Ann Oncol. 1998 Jun;9(6):653-6 [9681080.001]
  • [Cites] Oncology. 1999 Apr;56(3):177-80 [10202270.001]
  • [Cites] Anticancer Res. 1999 May-Jun;19(3B):2257-60 [10472340.001]
  • [Cites] Am J Clin Oncol. 2004 Dec;27(6):565-9 [15577433.001]
  • [Cites] Mod Pathol. 2006 Jul;19(7):907-13 [16648872.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3069-74 [16809731.001]
  • [Cites] BMC Cancer. 2006;6:190 [16846514.001]
  • [Cites] Br J Cancer. 2006 Oct 9;95(7):848-52 [16969352.001]
  • [Cites] JAMA. 2007 Jan 17;297(3):267-77 [17227978.001]
  • [Cites] Clin Colorectal Cancer. 2006 Nov;6(4):265-72 [17241511.001]
  • [Cites] Br J Cancer. 2007 Mar 26;96(6):896-902 [17325704.001]
  • [Cites] Am J Clin Oncol. 2007 Jun;30(3):319-24 [17551313.001]
  • [Cites] Cancer. 2007 Sep 15;110(6):1307-12 [17628484.001]
  • [Cites] Ann Surg Oncol. 2007 Nov;14(11):3202-9 [17705089.001]
  • [Cites] Dig Dis Sci. 2008 Feb;53(2):564-70 [17597402.001]
  • [Cites] Am J Clin Oncol. 2008 Apr;31(2):140-4 [18391597.001]
  • [Cites] Rev Recent Clin Trials. 2006 Jan;1(1):1-13 [18393776.001]
  • [Cites] Ann Oncol. 2001 Feb;12(2):183-6 [11300321.001]
  • (PMID = 18825277.001).
  • [ISSN] 1449-1907
  • [Journal-full-title] International journal of medical sciences
  • [ISO-abbreviation] Int J Med Sci
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 2.7.10.1 / Receptor, ErbB-2
  • [Other-IDs] NLM/ PMC2556051
  • [Keywords] NOTNLM ; differentiation / endothelial growth factor receptor (EGFR) / gallbladder cancer / her-2-neu / survival
  •  go-up   go-down


24. Takahashi Y: [Gastrointestinal cancer]. Gan To Kagaku Ryoho; 2004 Aug;31(8):1275-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The sensitivity of CEA, CA 19-9, is relatively high, especially in well-differentiated adenocarcinoma of gastric cancer with lymph node metastasis.
  • Half-life and doubling time of tumor markers is useful in some cases for the evaluation of operation and chemotherapy.
  • Recurrent diseases were detected between 5 months after detection by diagnostic imagings and 12 months before detection by diagnostic imagings (mean of 3.1+/-3.6 months before detection by diagnostic imagings) and between 10 months after detection by diagnostic imagings and 13 months before detection by diagnostic imagings (mean 2.2+/-3.9 months before detection by diagnostic imagings) by CEA and CA 19-9 monitorings, respectively.
  • [MeSH-minor] CA-19-9 Antigen / blood. Carcinoembryonic Antigen / blood. Colorectal Neoplasms / diagnosis. Esophageal Neoplasms / diagnosis. Humans. Predictive Value of Tests. Prospective Studies. Sensitivity and Specificity. Stomach Neoplasms / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15332558.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen
  • [Number-of-references] 18
  •  go-up   go-down


25. Trafalis DT, Geromichalos GD, Bountouroglou N, Koumbi D, Kontos M, Sougias D, Dalezis P, Karamanakos P, Papageorgiou A, Camoutsis C, Athanassiou AE: A preclinical survey on the efficacy of lactandrate in the treatment of colon carcinoma. J BUON; 2005 Apr-Jun;10(2):227-34

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A preclinical survey on the efficacy of lactandrate in the treatment of colon carcinoma.
  • PURPOSE: There has been a recent and dramatic increase in the pace of drug development for colorectal cancer which holds promise to further improve curative therapy.
  • We tested lactandrate, an alkylating ester of D-lactam androsterone, for antineoplastic activity against colon adenocarcinoma in vitro and in vivo.
  • MATERIALS AND METHODS: The cytostatic and cytotoxic activity of lactandrate were evaluated in vitro against 9 human colon adenocarcinoma cell lines.
  • The in vitro testing was performed with the sulforhodamine B (SRB) colorimetric assay and the mean concentrations of each drug that generated 50% (GI50) or total (100%) growth inhibition (TGI), as well as the drug concentrations that produced cytotoxicity against 50% of the cultured cells (IC50) were calculated.
  • The in vivo antitumour effect was determined against two rodent colon carcinomas, the Colon 26 and the relatively chemoresistant Colon 38 carcinoma, as well as against the human xenograft CX-1 colon carcinoma.
  • The more differentiated cell lines DLD-1 and HCC2998 appeared more resistant to the cytostatic effect of lactandrate.
  • In vivo, the compound produced a significant antitumour activity against Colon 26 and Colon 38, as well as a moderate antitumour effect against CX-1 colon carcinoma.
  • Therefore, lactandrate represents an important candidate drug for further clinical development.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17343334.001).
  • [ISSN] 1107-0625
  • [Journal-full-title] Journal of B.U.ON. : official journal of the Balkan Union of Oncology
  • [ISO-abbreviation] J BUON
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down






Advertisement